# Aberrant tau accumulation caused by MAPT mutations induces early pathological changes in axonal transport that are rescued by p38α inhibition.

- **DOI:** [10.1038/s41593-026-02266-4](https://doi.org/10.1038/s41593-026-02266-4)
- **Rating:** Sound (3.2 out of 5)
- **Verdict:** High-resolution in vivo imaging identifies early, pharmacologically reversible transport deficits in tauopathy, but pseudoreplicated culture analyses weaken the proposed tau-envelope mechanism.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1038%2Fs41593-026-02266-4

## Key claims

1. deficits in axonal transport arise in vivo at early stages of tau pathology, preceding tangle formation and neuronal death.
   - Support: Supported
   - Type: Primary finding
   - Basis: mouse-level evidence supports an early model-specific deficit, but very small female cohorts limit precision and generalisability
   - Location: Abstract; Results, Fig. 2
2. these deficits are reversed by inhibiting MAPK p38α.
   - Support: Supported
   - Type: Secondary
   - Basis: paired inhibitor experiments improve selected transport measures, though rescue is partial and treatment order is fixed
   - Location: Abstract; Results, Figs. 2–4
3. tau envelopes function as obstacles for axonal transport
   - Support: Tentative
   - Type: Secondary
   - Basis: colocalisation, pause association, and correlative microscopy do not independently manipulate envelope size or establish causation
   - Location: Results, Clusters of mutant tau on microtubules hinder axonal transport; Fig. 7
4. the activity of SB-239063 on axonal transport is largely dependent on the reduction of P301L tau phosphorylation levels.
   - Support: Tentative
   - Type: Secondary
   - Basis: phosphomutants are informative, but the inhibitor comparison being explained is non-significant and nested observations are not modeled
   - Location: Results, Fig. 6

## Strengths

- **Single-organelle cortical transport imaging** The two-photon assay follows BDNF-containing granules in cortico-cortical projections at substantially higher spatiotemporal resolution than the prior in vivo work described by the paper.
  - Dimension: contribution
  - Location: Results, Fig. 1
- **Convergent genetic and pharmacological controls** Doxycycline suppression, the rTg21221 WT-tau line, phosphomutant constructs, and two p38 inhibitors test complementary parts of the proposed pathway.
  - Dimension: methodological rigour
  - Location: Figs. 2–6; Extended Data Fig. 1g–j
- **Competing interpretations are discussed** The Discussion addresses contradictory transport studies, divergent taxol findings, incomplete rescue, and the possibility that the observed structures are small pathological aggregates rather than canonical envelopes.
  - Dimension: positioning
  - Location: Discussion, both subsections

## Limitations

- **Mechanistic analyses use clustered observations** Figs. 5–7 conduct inference on neurons or axons nested within three to five neuronal preparations; plotting preparation means does not account for that dependence.
  - Dimension: methodological rigour
  - Location: Figs. 5c,d, 6b,c and 7c–e,i
- **Mechanistic wording exceeds reported evidence** The envelope-obstacle claim is largely correlational, while phosphorylation dependence and envelope-size restoration are stated despite non-significant direct comparisons in Figs. 6 and 7.
  - Dimension: reporting
  - Location: Abstract; Figs. 6b,c and 7h,i; Discussion
- **Small and restricted in vivo cohorts** Central imaging comparisons use three to four mice per group and predominantly or exclusively female cohorts, limiting precision and generalisability despite paired designs.
  - Dimension: methodological rigour
  - Location: Figs. 2d, 3d and 4c,d legends

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Noted. Track selection is described differently in the legends and Methods, one comparison has two differently reported P values, and an in vivo efficacy statement cites cultured-neuron experiments.
  - Ethics approval: declared · Preregistration: not stated · Data availability: declared
- **Reference integrity:** Clean
  - 83 references in manuscript
  - 81 of 81 checkable references found in an index
  - 2 have no canonical index record — counted, but not index-checkable
  - 3 references confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
